Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Syndax Pharmaceuticals (SNDX) Receivables - Other (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 11 years of Receivables - Other data on record, last reported at $3.7 million in Q4 2025.

  • For Q4 2025, Receivables - Other rose 1.79% year-over-year to $3.7 million; the TTM value through Dec 2025 reached $3.7 million, up 1.79%, while the annual FY2025 figure was $3.7 million, 1.79% up from the prior year.
  • Receivables - Other reached $3.7 million in Q4 2025 per SNDX's latest filing, roughly flat from $3.7 million in the prior quarter.
  • Across five years, Receivables - Other topped out at $3.7 million in Q3 2025 and bottomed at $158000.0 in Q1 2022.
  • Average Receivables - Other over 5 years is $1.6 million, with a median of $1.3 million recorded in 2023.
  • Peak YoY movement for Receivables - Other: surged 781.65% in 2023, then plummeted 65.28% in 2024.
  • A 5-year view of Receivables - Other shows it stood at $182000.0 in 2021, then surged by 220.33% to $583000.0 in 2022, then surged by 110.46% to $1.2 million in 2023, then skyrocketed by 196.25% to $3.6 million in 2024, then grew by 1.79% to $3.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables - Other were $3.7 million in Q4 2025, $3.7 million in Q3 2025, and $2.0 million in Q2 2025.